Barr's conjugated estrogens ANDA
Executive Summary
FDA Commissioner Young and other agency officials recently met with Sen. D'Amato (R-NY) to discuss Barr's ANDA application for conjugated estrogens. Reportedly, the senator asked whether Barr is being treated fairly in regard to the product's review and whether there has been any further action on the application. Pomona, New York-based Barr submitted blood level studies for the application in accordance with an FDA decision on bioequivalence requirements for generic forms of Ayerst's Premarin. FDA had earlier rejected Barr's urinary excretion-based ANDA for estrogens. In a recent letter to FDA, Sen. Hatch (R-Utah) also expressed interest in FDA's review of Barr's generic conjugated estrogens.
You may also be interested in...
US FDA Drugs Center Ready To Break Down Silos On Regulatory Innovation
CDER Director Cavazzoni is promising to increase coordination and collaboration to accelerate broader adoption of innovative clinical trial designs and other approaches to speed drug development. A new "Quantitative Medicine Center of Excellence" illustrates the approach.
New OSP Director To Guide CDER-Wide IT Upgrades; System Enhancements Speed ANDA Assessments
Generic Drug Structured Assessment for Bioequivalence launched in 2023 and has been used in 40 ANDA reviews so far.
New EU Approvals
The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add two new products, including Ryzneuta, Evive Biotechnology's treatment for chemotherapy-induced neutropenia.